Dr Reddy’s And BMS Shake Hands On Pomalyst Settlement

Final Judgment Says Reddy’s Does Not Infringe Key Drug Substance Patent

Bristol Myers Squibb does not “expect generic entry in the US market prior to the first quarter of 2026” for its Pomalyst treatment for relapsed and refractory multiple myeloma, after reaching a settlement agreement with ANDA sponsor Dr Reddy’s Laboratories.

Clock disintegrates, time running out concept
Time is ticking for BMS' major patent cliff • Source: Piotr Adamowicz / Alamy Stock Photo

Dr. Reddy's Laboratories Ltd. and Bristol Myers Squibb’s Celgene have reached a settlement agreement in patent-litigation proceedings stemming from the Indian firm’s development of a generic version of the originator’s Pomalyst (pomalidomide) capsules.

A letter penned by counsel representing both firms directs a US district court in New Jersey to dismiss the case...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

Nexus Faces Five Year Wait On Injectable Minocycline

Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

test

uygukgigo

 
• By 

More from Business

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.